DUBAI, United Arab Emirates--(BUSINESS WIRE)--Aug. 14, 2017--
Masimo (NASDAQ:MASI)
announced today that the Dubai Health Authority (DHA), the government
organization that oversees the healthcare systems of Dubai, is
augmenting its current inventory of Masimo equipment and technology with
the implementation of Masimo Patient SafetyNet™*, a supplemental remote
monitoring and clinician notification system, at two hospitals in Dubai.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170813005035/en/
Masimo Patient SafetyNet enables information from bedside monitors, such
as Masimo Root® with the Radical-7® or wearable
Radius-7® Pulse CO-Oximeter®, to be accessible
from a central viewing station. When changes occur in measured values,
which may indicate deterioration in a patient’s condition, Patient
SafetyNet automatically sends wireless alerts directly to clinicians,
wherever they may be. In addition, Patient SafetyNet can automate the
transfer of patient data, including admission data, vital signs, early
warning scores (EWS), and other physiological parameters, directly to
hospital electronic medical record (EMR) systems, helping to improve
clinician workflows and reduce the possibility of transcription errors.
Dr. Andreas Taenzer and colleagues found in an 11-month study conducted
at Dartmouth-Hitchcock Medical Center that using Patient SafetyNet and
Masimo SET® pulse oximetry as part of a comprehensive alarm
management strategy reduced rescue events by 65% and intensive care unit
transfers by 48%, and as a result, reduced costs by $1,480,000.1,2 In
a subsequent article, they announced that after five years,
Dartmouth-Hitchcock had had zero preventable deaths or instances of
brain damage due to opioids since the installation of Patient SafetyNet.2
In 2016, after ten years, they reported achieving a 50% reduction in
unplanned ICU transfers and a 60% reduction in rescue events, despite
increases in patient acuity and occupancy.3
The two Dubai Health Authority medical centers implementing Patient
SafetyNet are Dubai Hospital (625 beds), which provides general medical
and surgical care, and Latifa Hospital (367 beds), which specializes in
maternal and child care. Dubai Hospital installed its first Patient
SafetyNet in 2013. Latifa Hospital is in the process of installing four
systems, with a further system planned for Dubai Hospital. “We are
excited to deepen our partnership with Masimo,” said Humaid Al Qatami,
Chairman of the Board and Director General of Dubai Health Authority.
“The Dubai Health Authority’s mission is to develop an integrated and
sustainable healthcare system that ensures our comprehensive services
achieve the highest international standards, and we believe that
Masimo’s monitoring devices, now even more connected to hospital
infrastructure through the power of Patient SafetyNet, will help us meet
that goal.”
“Patient SafetyNet, in conjunction with Masimo SET® pulse
oximetry, enables continuous supplemental monitoring of active patients
in post-surgical wards and can help save the lives of patients on
opioids, among many other benefits,” said Joe Kiani, Founder and CEO of
Masimo. “We applaud the Dubai Health Authority, dedicated to providing
no less than the best health care in the world, for recognizing the
importance of implementing such a proven and powerful centralized
monitoring and patient surveillance system.”
@MasimoInnovates |
#Masimo
References
-
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-and-After
Concurrence Study. Anesthesiology. 2010 Feb;112(2):282-7.
-
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience.
Anesthesia Patient Safety Foundation Newsletter Spring-Summer 2012.
Available online.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
*The use of the trademark SafetyNet is under license from University
HealthSystem Consortium.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 16 of the top 20
hospitals listed in the 2016-17 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect™ (MOC-9™) interface, enabling other companies to
augment Root with new features and measurement capabilities. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor, iSpO2®
pulse oximeter for smartphones, and the MightySat™ fingertip pulse
oximeter. Additional information about Masimo and its products may be
found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
References
-
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
-
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
-
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
-
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Estimate: Masimo data on file.
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Patient SafetyNet™. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo Patient SafetyNet, contribute to positive
clinical outcomes and patient safety; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions and unique advantages; as well as other factors discussed in
the "Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170813005035/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com